SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Inclusion Criteria: * non-small cell lung cancer patients with less than brain metastases * Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment * Patients who have not received intracranial local treatment before Exclusion Criteria: * Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds * Patients with hemorrhage in intracranial metastasis